Paper Details

  1. Home
  2. Paper Details

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.

Author: CasasnovasOlivier, GhoshNilanjan, KatakamSudhakar, KnappAndrea, LossosIzidore S, McCordRon, MehtaAmitkumar, MorschhauserFranck, NielsenTina, PalombaM Lia, SallesGilles, StevensDon

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The triplet regimen obinutuzumab-atezolizumab-lenalidomide showed promising efficacy and tolerability in patients with relapsed/refractory follicular lymphoma, with a complete response rate of 71.9% at the end of induction.
Paper Details　
Original Abstract of the Article :
We evaluated the triplet regimen obinutuzumab-atezolizumab-lenalidomide (G-atezo-len) for patients with relapsed/refractory (R/R) follicular lymphoma (FL) in an open-label, multicenter phase Ib/II study (BO29562; NCT02631577). An initial 3 + 3 dose-escalation phase to define the recommended phase II...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379261/

データ提供：米国国立医学図書館（NLM）

Obinutuzumab-Atezolizumab-Lenalidomide: A Trio Against Follicular Lymphoma

The fight against cancer is a challenging journey, akin to traversing a vast and unforgiving desert. This research delves into the world of hematologic malignancies, exploring the use of a novel triplet regimen of obinutuzumab-atezolizumab-lenalidomide (G-atezo-len) for patients with relapsed/refractory follicular lymphoma (FL). The researchers conducted an open-label, multicenter phase Ib/II study, evaluating the safety and efficacy of this combination therapy. The results showed a remarkable complete response rate at the end of the induction phase, suggesting the potential of this regimen to effectively combat relapsed/refractory follicular lymphoma.

A Promising Trio for Follicular Lymphoma

The study demonstrated a 71.9% complete response rate for the efficacy population at the end of induction, with a 36-month progression-free survival rate of 68.4%. While the regimen was well tolerated, a significant percentage of patients experienced adverse events, highlighting the importance of careful monitoring and management of side effects.

Navigating the Desert of Cancer Treatment

Follicular lymphoma is a challenging condition, and this research provides valuable insights into the potential of a novel triplet regimen for its treatment. It emphasizes the importance of continued research to develop effective and safe therapies for this and other forms of cancer.

Dr.Camel's Conclusion

This phase Ib/II study provides encouraging evidence for the efficacy of the obinutuzumab-atezolizumab-lenalidomide regimen in treating relapsed/refractory follicular lymphoma. While further research is needed, this research offers a promising new avenue for the treatment of this challenging disease.

Date :
  1. Date Completed 2022-02-02
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

34417444

DOI: Digital Object Identifier

PMC8379261

Related Literature

Article Analysis
・Effects of obinutuzumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.